Skip to content

Advertisement

Volume 9 Supplement 2

AIDS Vaccine 2012

  • Poster presentation
  • Open Access

A new strategy for repeated application of adenovirus based vectors: proof-of-concept in rhesus macaques challenged with SIVmac239

  • 1,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 1
Retrovirology20129 (Suppl 2) :P335

https://doi.org/10.1186/1742-4690-9-S2-P335

  • Published:

Keywords

  • Neutralize Antibody
  • Rhesus Macaque
  • Therapeutic Vaccine
  • Immunological Profile
  • Adenovirus Serotype

Background

It is well recognized that highly active antiretroviral therapy (HAART) can control HIV/AIDS and prolong patient’s life. However, HAART is associated with drug toxicity, drug resistant, and patient's affordability. Therefore, developing an effective therapeutic vaccine that could induce HIV-specific immune responses may provide a solution to reduce the need of antiretroviral therapy. Adenovirus based vaccines have been extensively evaluated as a vaccine vehicle for HIV/AIDS and a variety infectious diseases, however, it has been a major concern that anti-Ad5 neutralizing antibodies in general population or after the first dose of immunization can hinder the its practical application. The idea of using less prevalent adenovirus serotypes lack of long-term safety record including oncogeneicity. Moreover, any adenovirus serotype will inevitablely induce neutralizing antibodies after one single use which render the strategy of using more serotypes infeasible.

Methods

In this study, we explored a novel “one-size-fits-all” strategy, namely AVIP (Adenoviral Vector Infected PBMC), to circumvent the attenuated efficacy of Ad-based vaccines due to anti-Ad immunity.

Results

We demonstrated that this AVIP strategy can elicit SIV-specific responses in both Ad5-seropositive and Ad5-seronegative macaques. Interestingly, comparable SIV-specific but weaker Ad5-specific responses were elicited in Ad5-seronegative monkeys received AVIP immunization as compared to direct injection of Ad5-SIV vaccines. Then a cohort of Ad5-seropositive SIVmac239-infected monkeys received AVIP immunization with Ad5 vectors expressing SIVmac239 Gag, Pol and Env with HAART. After therapeutic immunization, SIV-specific response was induced in vaccinated monkeys whereas a slower responses were observed in non-vaccinated monkeys. The functional immunological profiles were also being detected, and we are also monitoring whether this immunological benefit would afford a virological benefit.

Conclusion

Our goal is to further develop the AVIP strategy as a simple but practically effective method for repeated delivery of Ad5-based vaccines in humans for HIV and other diseases.

Authors’ Affiliations

(1)
Guangzhou Institute and Biomedicine and Health (GIBH), Guangzhou, China
(2)
Comprehensive AIDS Research Center, Tsinghua University, Beijing, China

Copyright

© Sun et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement